Needham Reiterates Buy on Sarepta Therapeutics, Maintains $166 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and maintained a price target of $166.
May 20, 2024 | 10:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Sarepta Therapeutics and maintained a price target of $166.
The reiteration of a Buy rating and the maintenance of a $166 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100